Mirabegron + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Overactive Bladder (OAB)
Conditions
Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
Trial Timeline
Mar 15, 2021 → Jul 24, 2023
NCT ID
NCT04641975About Mirabegron + Placebo
Mirabegron + Placebo is a phase 3 stage product being developed by Astellas Pharma for Overactive Bladder (OAB). The current trial status is terminated. This product is registered under clinical trial identifier NCT04641975. Target conditions include Overactive Bladder (OAB), Pharmacokinetics of Mirabegron.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04641975 | Phase 3 | Terminated |
| NCT02787083 | Phase 3 | Terminated |
| NCT02216214 | Approved | Completed |
| NCT02086188 | Approved | Completed |
| NCT02092181 | Approved | Completed |
| NCT01284309 | Phase 1 | Completed |
| NCT00912964 | Phase 3 | Completed |
| NCT00662909 | Phase 3 | Completed |
| NCT00410514 | Phase 2 | Completed |
Competing Products
20 competing products in Overactive Bladder (OAB)